Pfizer Inc. (NYSE:PFE) received approval from the European Commission for breast cancer drug TALZENNA
Pfizer Inc. (NYSE:PFE) has received approval from the European Commission for its TALZENNA a breast cancer drug. This approval follows the medicine’s approval by the U.S. Food and Drug Administration in October 2018. “Today’s approval of TALZENNA for certain patients with advanced-stage breast cancer and an inherited BRCA mutation is the latest example of our successful precision medicine approach to drug development,” said Andreas Penk, regional president, Oncology international developed markets at Pfizer in a statement.
Technical Stock Analysis
Pfizer Inc. (NYSE:PFE), a Healthcare sector firm, traded 35.92 Million shares in last trading session and stock popped up 0.16% with closing price of $43.67 per share. Company gross margins represents its total sales revenue minus its cost of goods sold (COGS), divided by the total sales revenue earned by the company, expressed as a percentage. And its good to know that the higher that percentage, the more the company retains on each dollar of sales, to service its other costs and the debt obligations, and Pfizer Inc. (NYSE:PFE)’s gross margin stands at 79.60%.
Investment Worthy Stock or not?
For personal guess ROI is usually expressed as a percentage and is typically used for taking any financial decisions, for the purpose of comparing a Pfizer Inc. (NYSE:PFE)’s profitability or to compare the efficiency of different investments, hence, PFE return on investment (ROI) is 10.20%.
52-Week Range are valuable stats for watching Pfizer Inc. (NYSE:PFE)’s past year fluctuation as that gives investors an idea of how much the security has moved in the last year and whether it is trading near the top, middle or bottom of the range. Pfizer Inc. (NYSE:PFE)’s stock value has moved between $36.09 – 46.46 in last one year.
Analysts mean target price for Pfizer Inc. (NYSE:PFE) is $45.57 while analysts mean recommendation is 2.40.
Its weekly performance is 2.13% while year to date (YTD) performance is 0.05%.
Earnings per share growth is defined as the percentage change in normalised earnings per share over the previous 12 month period to the latest year end. It gives a good picture of the rate at which a company has grown its profitability. Pfizer Inc. (NYSE:PFE)’s EPS growth this year is -11.90%. For best decision making investors should look at Pfizer Inc. (NYSE:PFE)’s EPS growth for next year stands at 5.29%.